Kraig Biocraft Laboratories Nears Strategic Three-Year Government Collaboration to Expand Recombinant Spider Silk Production

Rhea-AI Summary

Kraig Biocraft Laboratories (OTCQB: KBLB) is finalizing a significant three-year collaboration agreement with a Southeast Asian government agency to expand its recombinant spider silk production. The agreement, expected to be signed by end of July 2025, will provide access to new rearing facilities, infrastructure, and technical resources.

The partnership aims to optimize and scale spider silk production through parallel rearing operations, eliminating single points of failure in the supply chain. The collaboration includes creating multiple independent facilities for parent strain and egg production, enhancing supply chain security and increasing throughput capacity. Work under this agreement is scheduled to begin in August 2025.

Positive

• Strategic access to new government rearing facilities and technical resources
• Implementation of parallel rearing operations to eliminate single points of failure
• Enhanced supply chain security through multiple independent facilities
• Increased production capacity and throughput potential

Negative

• Agreement not yet finalized, pending final signature
• Dependent on foreign government collaboration for expansion
• Implementation timeline and specific production targets not disclosed

News Market Reaction

+2.12%

1 alert

+2.12% News Effect

On the day this news was published, KBLB gained 2.12%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

ANN ARBOR, Mich., July 18, 2025 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Company" or "Kraig Labs"), a world leader in spider silk technology*, announces that it is finalizing a significant three-year collaborative agreement with a key government agency in Southeast Asia to expand the scale and security of its recombinant spider silk manufacturing platform.

This landmark agreement, expected to be signed before the end of July, marks the culmination of years of relationship-building and demonstrated performance by Kraig Labs and its proprietary spider silk technologies. The agreement is designed to accelerate the Company's growth by providing access to previously unavailable rearing facilities, supporting infrastructure, and technical resources.

Under the terms of this collaboration, Kraig Labs will work closely with government specialists to optimize and expand spider silk production. The collaboration will unlock new production capacity, enabling Kraig Labs to significantly scale its hybridized silkworm operations.

Importantly, this agreement also includes provisions for the creation of parallel rearing operations, a key component in the Company’s long-term roadmap to mitigate production risk and eliminate single points of failure. By distributing parent strain and egg production across multiple independent facilities, Kraig Labs is further securing its supply chain and increasing throughput capacity to meet future demand.

"We believe this collaboration is a transformative step forward in our mission to commercialize sustainable, cost-effective spider silk. This rare opportunity is due, in large part, to the team we’ve assembled, our commitment to excellence, and our progress in the field," said the Company’s COO, Jon Rice. "It provides us with strategic infrastructure and institutional support to grow our production footprint, while further reinforcing the stability and security of our operations through parallelized rearing and egg development systems."

Work under this agreement is anticipated to begin in August. This collaboration will serve as a foundational element of the Company’s expanding global spider silk manufacturing strategy, highlighting the growing confidence in the Company's pioneering biomaterials.

For the latest updates on Kraig Labs and its pioneering spider silk technologies, visit www.kraiglabs.com.

For details about other recent Kraig Labs advancements, please watch the Company's investor conference at www.kraiglabs.com/videos or on the Company's YouTube Channel https://www.youtube.com/@kraigbiocraftlaboratories2270.

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

* For a description of our historical leadership in this technology, please follow this link https://www.kraiglabs.com/world-leader/

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "estimated," "hopes," "if," "develops," "researching," "research," "pilot," "potential," "could" or other words or phrases of similar import. Forward looking statements include descriptions of the Company's business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, Inc.
(720) 288-8495
ir@KraigLabs.com

FAQ

What is the strategic partnership Kraig Biocraft (KBLB) announced in July 2025?

Kraig Biocraft announced a three-year collaboration agreement with a Southeast Asian government agency to expand its recombinant spider silk production, providing access to new rearing facilities and technical resources.

How will the new government collaboration affect KBLB's production capacity?

The collaboration will provide access to new rearing facilities and enable parallel production operations, significantly increasing throughput capacity and eliminating single points of failure in the supply chain.

When will Kraig Biocraft's new government partnership begin operations?

The partnership is expected to be signed by the end of July 2025, with operations scheduled to begin in August 2025.

What are the main benefits of KBLB's new production strategy?

The strategy includes parallel rearing operations, multiple independent facilities for parent strain and egg production, enhanced supply chain security, and increased production capacity.

How does this agreement impact Kraig Biocraft's manufacturing strategy?

The agreement serves as a foundational element of KBLB's expanding global spider silk manufacturing strategy, providing strategic infrastructure and institutional support for growth.